Costs continue to escalate
at alarming rates for cell
and gene therapies. Tokio
Marine HCC – Stop Loss
Group (TMHCC) offers a
solution to manage these
high cost events. TMHCC
has partnered with Emerging
Therapy Solutions (ETS) for
a best in class service to
positively impact the plan
and patient.
When TMHCC stop loss policyholders use ETS’s Programs of Excellence (POE) for gene therapy, they will benefit by receiving a 10% reduction in the specific deductible for the patient receiving gene therapy. ETS will also
provide suggested plan language for
incorporation of this program into the Plan
Document.
The 10% step down deductible has a minimum deduction of $15,000 and a maximum of $50,000. Please see TMHCC's Best Practices in Cell & Gene Therapy for examples of how the step down deductible can save your clients' money on cell and gene therapy treatments.
|
|
Please contact your regional marketing representative to learn more on how TMHCC in partnership with ETS can positively impact your clients' healthcare plans.
TMHCC is a leading provider of medical stop loss coverage provided through brokers, consultants and third-party administrators. By listening to the demands of the market, we have developed exceptional products, unparalleled resources and value-added services that set us apart in the industry. Visit our website to learn more about our innovative stop loss, Taft-Hartley, captive and organ transplant solutions.